Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
US7122173B2 · kind B2 · utility
1Cited by
2References
1Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 29, 2002 |
| Grant date | Oct 17, 2006 |
| Priority date | — |
| Expiry date | May 3, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P13/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising, as an active ingredient, a compound having a slowly-inactivating A-type K+ channel opening activity or a pharmaceutically acceptable salt thereof, and a method for screening agents for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising measuring a slowly-inactivating A-type K+ channel opening activity as an index.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.